MK-5172: Interim Phase II data

Interim data from both cohorts of a double-blind Phase II trial in 332 treatment-naïve patients with chronic HCV genotype 1 infection showed that 82.8-93% of patients receiving once-daily 100, 200, 400 or 800 mg MK-5172 plus standard of care (SOC; peginterferon alfa-2b and ribavirin) for 12 weeks achieved a cEVR, the primary endpoint, vs. 74.2% of patients who received SOC for 4 weeks followed by the addition of boceprevir. In the first cohort of 136 patients, 96.2% of patients receiving once-daily 100 mg MK-5172 plus SOC achieved an SVR 12 weeks after the end of treatment vs. 54.2% for the control arm. SVR12 rates were 86.7% for the 200 mg MK-5172 arm, 87% for the 400 mg MK-5172 arm and 81.5% for the 800 mg MK-5172 arm. Virologic failure was observed in 2.3% of patients receiving MK-5172. ...